Literature DB >> 16884317

Chronopharmacokinetics of ciclosporin and tacrolimus.

Massimo Baraldo1, Mario Furlanut.   

Abstract

The correct use of immunosuppressive drugs has a considerable influence on the prognosis of patients with organ transplants. The appropriate utilisation of the drugs involves the administration of an adequate dosage to reach the blood concentrations that will suppress the alloimmune response, while avoiding secondary toxicities. However, transplanted patients exhibit heterogeneous immunological responses and high inter- and intraindividual pharmacokinetic variabilities. One cause of these variabilities that is rarely considered is circadian rhythms. In vitro and in vivo experiments have clearly demonstrated that all organisms are highly organised according to an internal biological clock that influences various physiological functions. Considering that the absorption, distribution, metabolism and elimination of drugs is influenced by the physiological functions of the body, it is not surprising that the pharmacokinetic, and consequently the pharmacodynamic, profiles of drugs can be influenced by circadian rhythms. Ciclosporin, a mainstay immunosuppressive drug used following organ transplantation, displays minimum blood concentration (C(min)), maximum blood concentration (C(max)) and area under the blood concentration-time curve (AUC) in the morning that are generally higher than the corresponding parameters in the evening. These observations are supported by the ciclosporin total body clearance and elimination half-life in the morning, which are, on average, higher and shorter, respectively, than those in the evening. In addition, the disposition of tacrolimus is determined by the time of administration. The tacrolimus C(max) and AUC after the morning dose are significantly higher than those after the evening dose. Finally, the results reported in this review suggest considering more carefully the chronopharmacokinetics of tacrolimus and ciclosporin in order to obtain better results with fewer adverse effects. Significantly, the morning appears to be the best time for therapeutic monitoring using the C(min), C(max), concentration at 2 hours after dosing and AUC to modify dosages of tacrolimus and ciclosporin. Less certain are any conclusions about whether, in order to obtain better immunosuppressive control, higher doses must be administered when these drugs are given in the evening to compensate for the higher levels of interleukin-2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884317     DOI: 10.2165/00003088-200645080-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  77 in total

1.  Circadian variability in hemorrhagic stroke.

Authors:  Ilaria Casetta; Enrico Granieri; Francesco Portaluppi; Roberto Manfredini
Journal:  JAMA       Date:  2002-03-13       Impact factor: 56.272

Review 2.  Immunosuppressant drugs--the role of therapeutic drug monitoring.

Authors:  A Johnston; D W Holt
Journal:  Br J Clin Pharmacol       Date:  2001       Impact factor: 4.335

3.  Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy.

Authors:  T Iwahori; H Takeuchi; N Matsuno; Y Johjima; O Konno; Y Nakamura; K Hama; M Uchiyama; T Ashizawa; K Okuyama; T Nagao; M Abudoshukur; T Hirano; K Oka
Journal:  Transplant Proc       Date:  2005-05       Impact factor: 1.066

4.  Intragastric pH and pharmacokinetics of intravenous ranitidine during sinusoidal and constant-rate infusions.

Authors:  S W Sanders; A L Bishop; J G Moore
Journal:  Chronobiol Int       Date:  1991       Impact factor: 2.877

5.  Chronopharmacokinetics and cardiovascular effects of nifedipine.

Authors:  B Lemmer; G Nold; S Behne; R Kaiser
Journal:  Chronobiol Int       Date:  1991       Impact factor: 2.877

6.  Chronopharmacokinetics of nicotine.

Authors:  J M Gries; N Benowitz; D Verotta
Journal:  Clin Pharmacol Ther       Date:  1996-10       Impact factor: 6.875

7.  Chronopharmacology of tacrolimus in rats: toxicity and efficacy in a mouse-to-rat intestinal transplant model and its pharmacokinetic profile.

Authors:  H Uchida; E Kobayashi; Y Ogino; K Mizuta; H To; R Okabe; K Hashizume; A Fujimura
Journal:  Transplant Proc       Date:  1999-11       Impact factor: 1.066

8.  Twenty-four-hour analysis of lymphocyte subpopulations and cytokines in healthy subjects.

Authors:  S Palm; E Postler; H Hinrichsen; H Maier; P Zabel; W Kirch
Journal:  Chronobiol Int       Date:  1996-12       Impact factor: 2.877

9.  More on the need for circadian, circaseptan and circannual optimization of cyclosporine therapy.

Authors:  T Liu; M Cavallini; F Halberg; G Cornelissen; J Field; D E Sutherland
Journal:  Experientia       Date:  1986-01-15

10.  Administration time-dependent toxicity of a new immunosuppressive agent, tacrolimus (FK 506).

Authors:  A Fujimura; A Ebihara
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

View more
  10 in total

1.  Assessment of the impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisolone.

Authors:  Jian Xu; Julia Winkler; Sreedharan Nair Sabarinath; Hartmut Derendorf
Journal:  AAPS J       Date:  2008-06-25       Impact factor: 4.009

Review 2.  Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients.

Authors:  Sarah A Cross; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study.

Authors:  Christin C Rogers; Rita R Alloway; J Wesley Alexander; Michael Cardi; Jennifer Trofe; Alexander A Vinks
Journal:  Clin Transplant       Date:  2008 May-Jun       Impact factor: 2.863

Review 4.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

Authors:  Jeannine S McCune; Meagan J Bemer
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

5.  Calcineurin inhibitors differentially alter the circadian rhythm of T-cell functionality in transplant recipients.

Authors:  Sarah Leyking; Karin Budich; Kai van Bentum; Stephan Thijssen; Hashim Abdul-Khaliq; Danilo Fliser; Martina Sester; Urban Sester
Journal:  J Transl Med       Date:  2015-02-06       Impact factor: 5.531

Review 6.  Post-transcriptional control of the mammalian circadian clock: implications for health and disease.

Authors:  Marco Preußner; Florian Heyd
Journal:  Pflugers Arch       Date:  2016-04-23       Impact factor: 3.657

7.  Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation.

Authors:  Pere Fontova; Helena Colom; Raül Rigo-Bonnin; Lisanne N van Merendonk; Anna Vidal-Alabró; Nuria Montero; Edoardo Melilli; Maria Meneghini; Anna Manonelles; Josep M Cruzado; Juan Torras; Josep Maria Grinyó; Oriol Bestard; Nuria Lloberas
Journal:  Front Pharmacol       Date:  2021-03-17       Impact factor: 5.810

8.  Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers.

Authors:  A van Rongen; L Kervezee; Mje Brill; H van Meir; J den Hartigh; H-J Guchelaar; J H Meijer; J Burggraaf; F van Oosterhout
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-07-24

9.  Predictive engines based on pharmacokinetics modelling for tacrolimus personalized dosage in paediatric renal transplant patients.

Authors:  Manuel Prado-Velasco; Alberto Borobia; Antonio Carcas-Sansuan
Journal:  Sci Rep       Date:  2020-05-05       Impact factor: 4.379

10.  Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients.

Authors:  Marte Theie Gustavsen; Karsten Midtvedt; Ida Robertsen; Jean-Baptiste Woillard; Jean Debord; Rolf Anton Klaasen; Nils Tore Vethe; Stein Bergan; Anders Åsberg
Journal:  Clin Transl Sci       Date:  2020-07-11       Impact factor: 4.689

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.